---
schema_version: "secwatch.filing_event.v1"
accession: "0000014272-22-000112"
form_type: "8-K"
ticker: "BMY"
cik: "0000014272"
company_name: "BRISTOL MYERS SQUIBB CO"
filed_at: "2022-04-29T23:59:59+00:00"
generated_at: "2026-06-26T02:33:04.778361+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Bristol-Myers Q1 revenue $11.6B (+5%); Non-GAAP EPS $1.96 (+13%)

## Summary
- Revenue $11.648B, +5% YoY (7% ex FX); U.S. revenue $7.7B (+10%).
- GAAP EPS $0.59 (down 34%); Non-GAAP EPS $1.96 (up 13%); net $(0.10) Acquired IPRD impact.
- In-line products +8% (Eliquis $3.2B +11%, Opdivo $1.9B +12%).
- Revlimid $2.8B (-5%) and Abraxane $214M (-32%) as LOE pressures continue.
- FDA approved Opdualag (melanoma) and Camzyos (cardiomyopathy) in Q1.

## SEC filing metadata
- accession: 0000014272-22-000112
- form_type: 8-K
- ticker: BMY
- cik: 0000014272
- company_name: BRISTOL MYERS SQUIBB CO
- filed_at: 2022-04-29T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/14272/000001427222000112/0000014272-22-000112-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/14272/000001427222000112/bmy-20220429.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000014272-22-000112
- JSON: https://secwatch.observer/filing/0000014272-22-000112.json
- Plain text: https://secwatch.observer/filing/0000014272-22-000112.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.